Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0.59)
# 3,734
Out of 4,827 analysts
48
Total ratings
22.86%
Success rate
-29.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $24.65 | - | 2 | Apr 23, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $4.34 | - | 4 | Apr 1, 2025 | |
| GLYC GlycoMimetics | Initiates: Overweight | n/a | $0.24 | - | 1 | Mar 21, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $5.32 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $13.13 | -0.91% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $1.28 | - | 2 | Mar 7, 2025 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $7.10 | - | 1 | Feb 21, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $36.14 | - | 4 | Feb 19, 2025 | |
| CDTX Cidara Therapeutics | Assumes: Overweight | n/a | $19.15 | - | 1 | Jan 27, 2025 | |
| INCY Incyte | Reiterates: Neutral | n/a | $59.73 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.04 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.10 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $96 | $28.69 | +234.61% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.71 | - | 2 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $29.79 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $118.39 | +146.64% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $429.60 | -13.87% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.39 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.29 | - | 1 | May 30, 2017 |
Summit Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $24.65
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.34
Upside: -
GlycoMimetics
Mar 21, 2025
Initiates: Overweight
Price Target: n/a
Current: $0.24
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.32
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $13.13
Upside: -0.91%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.28
Upside: -
Prothena Corporation
Feb 21, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.10
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $36.14
Upside: -
Cidara Therapeutics
Jan 27, 2025
Assumes: Overweight
Price Target: n/a
Current: $19.15
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $59.73
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.04
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.10
Upside: -
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $28.69
Upside: +234.61%
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.71
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.79
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $118.39
Upside: +146.64%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $429.60
Upside: -13.87%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.39
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.29
Upside: -